Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial
In this study, the benefit and safety of atorvastatin (statin) and/or aspirin as adjuvant therapy will be compared with the control group receiving usual care for management of COVID-19. Atorvastatin will be prescribed as 40 mg oral tablets once daily for ten days or until discharge, whichever is earlier. The dose of aspirin will be 75 mg once daily for ten days or until discharge, whichever is earlier. All other therapies will be administered according to the institute ’s COVID-19 treatment protocol and the treating physician’s clinical judgment.Main outcomesAll study participants will be prospectively followed up for...
Source: Trials - October 30, 2020 Category: Research Source Type: clinical trials
NiaMIT Continuation With Early-stage Mitochondrial Myopathy Patients
Condition: Mitochondrial Myopathies Intervention: Dietary Supplement: Niacin Sponsors: University of Helsinki; Helsinki University Central Hospital; Institute for Molecular Medicine Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 4, 2020 Category: Research Source Type: clinical trials
